<p><strong>Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML)</strong>: occurred in patients exposed to Olaparib, and the majority of reports were fatal. Monitor patients for hematological toxicity at baseline and monthly thereafter. Discontinue if MDS/AML is confirmed.<br />
<br />
<strong>Pneumonitis</strong>: occurred in patients exposed to Olaparib, and some cases were fatal. Interrupt treatment if pneumonitis is suspected. Discontinue if pneumonitis is confirmed.<br />
<br />
<strong>Embryo-Fetal Toxicity</strong>: Olaparib can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.</p>